The attached document contains a new Request for Proposal (RFP) from Pfizer’s Global Medical Grants program. While Pfizer recognizes many institutions and healthcare professionals around the globe are prioritizing challenges associated with the COVID-19 pandemic, we are cognizant that the healthcare and patient community will continue to benefit from ongoing support for research, improvement science, and education in spite of this crisis. It is in this spirit that Pfizer will continue our grants program by publishing RFPs that have been planned for 2020.

Thank you in advance for all that you are doing to improve the care of patients. Pfizer is proud to be able to support these efforts through this grants program.

Please contact the Global Medical Grants team at GMG@pfizer.com if you have any questions or would like to be temporarily removed from our mailing list.
Pfizer Announces

Gram Negatives Pathogens & Antimicrobial Resistance: Local Data Generation in Latin America

Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.
II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>Argentina, Brazil, Chile, Colombia, Costa Rica, Equador, Guatemala, Honduras, México, Panamá, Peru, Uruguay</th>
</tr>
</thead>
</table>
| Applicant Eligibility Criteria | • Only organizations are eligible to receive grants, not individuals or medical practice groups.  
• The institution and principal investigator (PI) must be based in one of the eligible countries noted above.  
• The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.  
• Applicant must be affiliated with a host institution. |

III. Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>June 1, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area</td>
<td>Anti-infectives</td>
</tr>
</tbody>
</table>
| General Area of Interest for this RFP: | Projects that will be considered for Pfizer support will focus on studies evaluating the burden of gram negative multidrug resistant pathogens, including evolving epidemiology:  
1. Gram negative infection burden in different patient profile:  
   i. age cohorts (e.g., eldery adult, infants versus time of colonization and/or infection)  
   ii. clinical condition or patient population (e.g., individuals at increased risk of MDR infection in critical care sector, immunosuppressed versus type of infection)  
2. colonization in different patient profile (critical, immunosuppressed patient) and relationship with infection development  
3. Genotypic and phenotypic isolates characterization – (molecular characterization of Gram negative MDR)  
4. Gram negative MDR trend retrospectively and/or prospectively in immunosuppressed/severe ill patient |
5. Impact of prescriptive behavior on the evolution of Gram negative MDR pathogens
6. Gram negative National repository database
7. Registry repository of patients with Gram negative MDR infection
8. Incidence of gram negative MDR superinfections in ICU related to COVID-19 infection

**Expected Approximate Monetary Range of Grant Applications:**
- The estimated total available budget related to this RFP is $100,000.00 USD. Pfizer expects to support up to 5 grants.

**Key Dates:**
- RFP release date: June 1, 2020
- Grant Application due date: July 30, 2020
  Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5).
- Anticipated Grant Award Notification Date: September 1, 2020
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start/Dates: November 2020 – November 2021

**How to Submit:**
- Please go to [www.cybergrants.com/pfizer/Research](http://www.cybergrants.com/pfizer/Research) and sign in. First-time users should click “Create your password”.
- In the application:
  - For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes
  - Select the following Competitive Grant Program Name: **2020 HU – R – Anti-infectives LATAM**
  - Select the following Primary Area of Interest: Anti-infectives
- Requirements for submission:
  - Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field.
  - Please submit your application in English.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed.
### Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jessica Romano, jessica.romano@pfizer.com, with the subject line: “General Research RFP: Anti-infectives LATAM.”
- Please click [here](#) to view Frequently Asked Questions regarding the Competitive Grant Program.

### Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

### Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.
# Appendix A

## General RFP Submission Requirements

Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

<table>
<thead>
<tr>
<th><strong>Goals and Objectives</strong></th>
<th>• Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assessment of Need for the Project</strong></td>
<td>• This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question</td>
</tr>
</tbody>
</table>
| **Target Audience** | • Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population  
• Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population |
| **Project Design and Methods** | • Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan |
| **Innovation** | • Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project |
| **Evaluation and Outcomes** | • Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures  
• Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines |
| **Anticipated Project Timeline** | • Provide an anticipated timeline for your project including project start/end dates |
| **Additional Information** | • If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here  
• Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant’s career. |
<table>
<thead>
<tr>
<th>Organization Detail</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>• This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project</td>
<td>• Bibliography of relevant references.</td>
</tr>
</tbody>
</table>